ABVX Abivax SA Forecast, Technical & Fundamental Analysis
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases... Show more
ABVX is expected to report earnings to fall 14.71% to -60 cents per share on September 21
Q2'26
Est.
$-0.60
Q1'26
Missed
by $0.10
Q4'25
Missed
by $0.54
Q3'25
Missed
by $1.79
Q2'25
Missed
by $0.70
The last earnings report on May 22 showed earnings per share of -70 cents, missing the estimate of -60 cents. With 453.82K shares outstanding, the current market capitalization sits at 10.00B.
A.I.dvisor indicates that over the last year, ABVX has been loosely correlated with IMNN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABVX jumps, then IMNN could also see price increases.
ABVX in downward trend: 10-day moving average broke below 50-day moving average on August 21, 2026
The 10-day moving average for ABVX crossed bearishly below the 50-day moving average on August 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABVX as a result. In of 46 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ABVX turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at .
ABVX moved below its 50-day moving average on August 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ABVX entered a downward trend on August 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVX advanced for three days, in of 173 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ABVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.492) is normal, around the industry mean (20.202). P/E Ratio (0.000) is within average values for comparable stocks, (22.945). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.854). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (192.308) is also within normal values, averaging (443.091).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
